DeepMed Research

ISTITUTO ONCOLOGICO VENETO

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.ioveneto.it

Clinical Trials

OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate

Recruiting

Conditions: Oligometastatic Prostate Carcinoma

First Posted Date: 2024-02-22

Last Posted Date: 2025-04-17

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 150

Registration Number: NCT06273345

Locations: 🇮🇹
Istituto Oncologico Veneto IRCCS, Padova, Italy
🇮🇹
Ospedali Riuniti Padova Sud, Padova, Italy
🇮🇹
Ospedale di Bressanone, Bressanone, Bolzano, Italy

and more 9 locations

A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

Not Applicable

Recruiting

Conditions: Non-muscle Invasive Bladder Cancer

Interventions: Device: Hydeal Cyst®

First Posted Date: 2024-02-07

Last Posted Date: 2025-05-21

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 200

Registration Number: NCT06245603

Locations: 🇮🇹
Azienda Ospedale Università Padova, Padova, Italy
🇮🇹
Ospedali Riuniti Padova Sud, Padova, Italy
🇮🇹
Policlinico Paolo Giaccone, Palermo, Italy

and more 6 locations

Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)

Phase 2

Recruiting

Conditions: Pleural Mesothelioma

Interventions: Drug: Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab

First Posted Date: 2023-12-04

Last Posted Date: 2025-03-11

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 40

Registration Number: NCT06155279

Locations: 🇮🇹
Humanitas Gavazzeni, Bergamo, Italia/Bergamo, Italy
🇮🇹
Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹
Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy

and more 5 locations

ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study

Not Applicable

Recruiting

Conditions: Colorectal Adenocarcinoma

Interventions: Dietary Supplement: Impact Oral®

First Posted Date: 2023-11-18

Last Posted Date: 2025-01-13

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 200

Registration Number: NCT06134440

Locations: 🇮🇹
Istituto Oncologico Veneto IRCCS, Padova, Italy

Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management

Recruiting

Conditions: Pleomorphic Lobular Breast Carcinoma in Situ
Breast Florid Lobular Carcinoma in Situ

Interventions: Procedure: Surgical wide local excision
Procedure: Cavity shaving
Procedure: Excision margin surgical clearance
Radiation: Adjuvant Radiotherapy
Biological: Adjuvant Hormone Therapy

First Posted Date: 2023-11-15

Last Posted Date: 2023-11-18

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 250

Registration Number: NCT06133465

Locations: 🇮🇹
Istituto Oncologico Veneto IRCCS, Padova, Italy

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients

Phase 1

Active, not recruiting

Conditions: Glioblastoma, IDH-wildtype
MGMT-Methylated Glioblastoma

Interventions: Drug: Regorafenib
Drug: Temozolomide

First Posted Date: 2023-10-23

Last Posted Date: 2024-12-24

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 36

Registration Number: NCT06095375

Locations: 🇮🇹
Istituto Oncologico Veneto IRCCS, Padova, Italy
🇮🇹
Humanitas Research Hospital, Rozzano, Italy

Risk-Based Breast Screening in Young Women

Not Applicable

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Diagnostic Test: Personalized screening protocol

First Posted Date: 2023-01-09

Last Posted Date: 2023-10-12

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 10269

Registration Number: NCT05675085

Locations: 🇮🇹
Istituto Oncologico Veneto (IRCCS), Padova, Italy

An Integrated Radio-immunological Approach

Recruiting

Conditions: Glioma, Malignant

First Posted Date: 2022-03-04

Last Posted Date: 2025-03-11

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 40

Registration Number: NCT05267509

Locations: 🇮🇹
University Hospital, Padova, Italy

First Line Osimertinib in the Real World: an Inter-regional Prospective Study

Completed

Conditions: EGF-R Positive Non-Small Cell Lung Cancer

Interventions: Drug: Osimertinib 80 MG

First Posted Date: 2021-07-16

Last Posted Date: 2023-11-13

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 200

Registration Number: NCT04965701

Locations: 🇮🇹
Istituto Oncologico Veneto, Padova, Italy

Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study

Completed

Conditions: Solid Tumor, Adult

First Posted Date: 2021-03-23

Last Posted Date: 2023-11-01

Lead Sponsor: Istituto Oncologico Veneto IRCCS

Target Recruit Count: 761

Registration Number: NCT04811781

Locations: 🇮🇹
istituto Oncologico Veneto -UOSD Melanoma, Padova, PD, Italy
🇮🇹
Aulss1 Dolomiti, Belluno, Italy
🇮🇹
Istituto Oncologico Veneto -UOC Oncologia 1, Padova, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy